{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-101974","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.880636+00:00","generated_at":"2026-05-17T21:24:19.209340+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Syndax Q2 Revuforj revenue $28.6M (+43% QoQ); sNDA for mNPM1 AML with Priority Review","bullets":["Revuforj net revenue $28.6M in Q2 2025, 43% increase over Q1 2025.","Niktimvo net revenue $36.2M (Incyte-reported); Syndax collaboration revenue $9.4M.","sNDA for Revuforj in R/R mNPM1 AML granted Priority Review; PDUFA Oct 25, 2025.","Cash, cash equivalents and investments $517.9M; expect funding to profitability.","Net loss $71.8M ($0.83/sh) vs $68.1M ($0.80/sh) year ago."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-101974","json":"https://secwatch.observer/filing/0000950170-25-101974.json","markdown":"https://secwatch.observer/filing/0000950170-25-101974.md","text":"https://secwatch.observer/filing/0000950170-25-101974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/0000950170-25-101974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:24:19.209340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}